Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Manage your formulary budget
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Treatment of allograft rejection with mycophenolic acid, its morpholinoethylester and derivatives thereof|
|Abstract:||The compounds and pharmaceutical compositions of Formula A, wherein Z is hydrogen or --C(O)R, Y is hydrogen or morpholinoethyl, and where R is lower alkyl or aryl, and the pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, particularly for treatment of allograft rejection, especially including cardiac allograft rejection, pancreatic allograft rejection and renal allograft rejection, and for treating autoimmune diabetes. ##STR1##|
|Inventor(s):||Allison; Anthony C. (Belmont, CA), Eugui; Elsie M. (Belmont, CA), Nelson; Peter H. (Los Altos, CA), Gu; Chee-Liang L. (Sunnyvale, CA), Lee; William A. (Palo Alto, CA)|
|Assignee:||Syntex (U.S.A.) Inc. (Palo Alto, CA)|
|Filing Date:||Aug 17, 1988|
|Claims:||1. A method of immunosuppressive treatment, particularly for treatment of allograft rejection in mammals, which comprises administering to a mammal in need thereof 0.4 to 30 mg/kg per day of a compound represented by the formula: ##STR8## wherein: Y is hydrogen and |
Z is hydrogen or --C(O)R,
where R is lower alkyl or aryl; or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 comprising a method of treating cardiac allograft rejection, pancreatic allograft rejection or renal allograft rejection.
3. The method of claim 2 wherein Z is hydrogen.
4. The method of claim 1 wherein Z is hydrogen.